Inventor · disambiguated record
Susannah Brydges
Also filed as: BRYDGES SUSANNAH
6 granted patents·8 pending applications·4 citations·filing 2018–2025
72Inventor score
Top patents by PatentIndex Score
14 records- 0181US11111504B2Methods for scarless introduction of targeted modifications into targeting vectorsREGENERON PHARMA·Filed 2020·Granted Sep 7, 2021·1 cites·29 claims
- 0280US11470828B2Rodent model of mood disordersREGENERON PHARMA·Filed 2020·Granted Oct 18, 2022·1 cites·24 claims
- 0379US11064685B2Non-human animal models of retinoschisisREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Jul 20, 2021·1 cites·29 claims
- 0479US11021719B2Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Granted Jun 1, 2021·1 cites·30 claims
- 0574US2025248377A1Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra geneREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0670US12082565B2Non-human animals models of retinoschisisREGENERON PHARMA·Filed 2021·Granted Sep 10, 2024·0 cites·26 claims
- 0770US2023123787A1Rodent model of mood disordersREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 0864US11499164B2Methods for scarless introduction of targeted modifications into targeting vectorsREGENERON PHARMA·Filed 2021·Granted Nov 15, 2022·0 cites·29 claims
- 0964US2022192165A1Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra geneREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1063US2021261985A1Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1161US2025049006A1Non-human animals comprising humanized ace2 and tmprss lociC/O REGENERON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1258US2025017183A1Non-human animals comprising a modified cacng1 locusREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1352US2023232796A1Non-human animals comprising a humanized ace2 locusREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1450US2023081547A1Non-human animals comprising a humanized klkb1 locus and methods of useREGENERON PHARMA·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →